Seven Fleet Capital Management LP Acquires Shares of 51,024 BioCryst Pharmaceuticals, Inc. $BCRX

Seven Fleet Capital Management LP acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 51,024 shares of the biotechnology company’s stock, valued at approximately $510,240,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada raised its stake in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 1,458 shares during the period. Cetera Investment Advisers lifted its holdings in BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,494 shares during the last quarter. Captrust Financial Advisors boosted its position in BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 1,527 shares during the period. Legato Capital Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 10.0% in the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,172 shares during the last quarter. Finally, Creative Planning increased its holdings in shares of BioCryst Pharmaceuticals by 2.6% in the third quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock valued at $672,000 after purchasing an additional 2,280 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $9.83 on Thursday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22. The company has a market capitalization of $2.51 billion, a PE ratio of -6.55 and a beta of 0.55. The company’s 50-day simple moving average is $9.68 and its 200 day simple moving average is $9.02.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business’s revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.15 EPS. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BCRX. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Finally, Needham & Company LLC decreased their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.